Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Banc of America Cuts Genentech Estimates


Genentech DNA said its Phase III study of Avastin in breast cancer didn't meet its primary endpoint. Banc of America cut its EPS estimates on Genentech.

Analyst Michael King says he had anticipated the news. He notes other details concerning the trial's outcome were scant. King reminds investors that Genentech has always stated colorectal cancer is its registration strategy for Avastin. King remains confident of the likelihood of a positive outcome in Avastin's Phase III colorectal cancer trial; he expects these results in mid-2003.

The analyst cuts his EPS estimates to bring them more in line with management guidance: for 2002, from $0.97 to $0.95; for 2003, from $1.23 to $1.09; for 2004, from $1.48 to $1.33; for 2005, from $1.80 to $1.64; for 2006, from $2.12 to $1.95; and for 2007, from $2.47 to $2.27. He rates the shares market perform.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus